Evaluation Of Pessaries In Twin Pregnancies With A Short Cervix (25 mm) Between 20-28 WG (EPEGE)
Overview
Randomized, opened multicentric study evaluating the Effectiveness of Pessary in the patients with a Gemellary pregnancy and a collar runs between 20 and 28 weeks of amenorrhoea
Full Title of Study: “Evaluation Of Pessaries In Twin Pregnancies With A Short Cervix (25 mm) Between 20-28 WG”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: None (Open Label)
- Study Primary Completion Date: June 2011
Detailed Description
Randomized, opened multicentric study evaluating the Effectiveness of Pessary in the patients with a Gemellary pregnancy and a collar runs between 20 and 28 weeks of amenorrhoea To show that the use of pessary makes it possible to lengthen the duration of the pregnancy of at least 10 days in patients with a twin pregnancy and a uterine collar length < = 25 mm measured by echography between 20 and 28 SA compared to the group controls.
Interventions
- Device: Silicon ring positioned in the vagina, around the cervix
- Silicon ring positioned in the vagina, around the cervix
Arms, Groups and Cohorts
- Experimental: 1
- Silicon ring positioned in the vagina, around the cervix
- Experimental: 2
- Silicon ring positioned in the vagina, around the cervix
Clinical Trial Outcome Measures
Primary Measures
- Demonstrate the profit of 10 days in the pessary group compared to control.
- Time Frame: at least 10 days
- Demonstrate the profit of 10 days in the pessary group compared to control
Secondary Measures
- To evaluate and compare the frequency of the childbirth < 34 SA
- Time Frame: before 34 weeks
- Deliveries (<34WG)
- Time Frame: 34 weeks
- Deliveries (<34WG)
- Evaluate the rate of side effects of pessaries
- Time Frame: during the pessaries
- Evaluate the rate of side effects of pessaries
- Neonatal outcome
- Time Frame: before 28 weeks
- Neonatal outcome
Participating in This Clinical Trial
Inclusion Criteria
- Age > 18 years (legal majority in France) – Inclusion pessary positioning before 28 WG – Twin pregnancies, mono or dichorionic, diamniotic – Transvaginal cervical length ( 25mm between 20 et 28 WG – Intact membranes – No signs of infection (negative urine culture, CRP <10mg/l , blood white cell count <15000/ml) – Patient accepting follow-up – Covered by health insurance for France Exclusion Criteria:
- Cerclage – No more cervix – Chorioamnionitis – Abnormal CTG – Placenta praevia – Abruptio – Bleeding – PROM – Singleton or multiple >2 – Monochorionic monoamniotic twin pregnancy – IUGR – Preeclampsia or other PIH – TTTS – Uncontrolled diabetes – Other maternal of fetal pathology responsible for preterm deliveries – Patient included in other therapeutic trials – Patient without legal freedom to consent – Homeless or no fixed address
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Assistance Publique – Hôpitaux de Paris
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Jacky NIZARD, CCA, Principal Investigator, Assistance Publique – Hôpitaux de Paris
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.